Four-year antibody persistence and response to a booster dose of a pentavalent MenABCWY vaccine administered to healthy adolescents and young adults

Emerging experience with meningococcal serogroup B protein vaccines

(2017) Daniela Toneatto et al.   Expert Review of Vaccines

Persistence of Bactericidal Activity at 4 Years After 2 Primary Doses of a Recombinant, 4-Component, Meningococcal Serogroup B Vaccine (4CMenB) and Response to a Booster Dose in Adolescents and Young Adults

(2017) Terry Nolan et al.   Open Forum Infectious Diseases

The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection

(2016) Ray Borrow et al.   Expert Review of Vaccines

The Global Evolution of Meningococcal Epidemiology Following the Introduction of Meningococcal Vaccines

(2016) Stephen I. Pelton   JOURNAL OF ADOLESCENT HEALTH

Clinical experience with the meningococcal B vaccine, Bexsero ® : Prospects for reducing the burden of meningococcal serogroup B disease

(2016) Philip S. Watson et al.   VACCINE

Neisseria meningitidisinfection: who, when and where?

(2015) Elena Gianchecchi et al.   Expert Review of Anti-Infective Therapy

Persistence of Meningococcal Antibodies and Response to a Third Dose After a Two-dose Vaccination Series with Investigational MenABCWY Vaccine Formulations in Adolescents

(2015) Xavier Saez-Llorens et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Safety and immunogenicity of a four-component meningococcal group B vaccine (4CMenB) and a quadrivalent meningococcal group ACWY conjugate vaccine administered concomitantly in healthy laboratory workers

(2015) Jamie Findlow et al.   VACCINE

Immunogenicity and safety of investigational vaccine formulations against meningococcal serogroups A, B, C, W, and Y in healthy adolescents

(2015) Xavier Saez-Llorens et al.   Human Vaccines & Immunotherapeutics

Serogroup W meningococcal disease: global spread and current affect on the Southern Cone in Latin America

(2014) R. ABAD et al.   EPIDEMIOLOGY AND INFECTION

Antibody Persistence and Booster Response of a Quadrivalent Meningococcal Conjugate Vaccine in Adolescents

(2014) Roger Baxter et al.   JOURNAL OF PEDIATRICS

Antibody Persistence After Primary and Booster Doses of a Quadrivalent Meningococcal Conjugate Vaccine in Adolescents

(2014) Roger Baxter et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

The current situation of meningococcal disease in Latin America and recommendations for a new case definition from the Global Meningococcal Initiative

(2013) Marco Aurélio P Sáfadi et al.   Expert Review of Vaccines

Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials

(2013) Timo Vesikari et al.   LANCET

Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study

(2012) María Elena Santolaya et al.   LANCET

Antibody Persistence and Response to a Booster Dose of a Quadrivalent Conjugate Vaccine for Meningococcal Disease in Adolescents

(2012) Robert M. Jacobson et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Meningococcal disease: Clinical presentation and sequelae

(2012) David Pace et al.   VACCINE

Importance of circulating antibodies in protection against meningococcal disease

(2012) Kim S. Erlich et al.   Human Vaccines & Immunotherapeutics

Development of an Automated, High-Throughput Bactericidal Assay That Measures Cellular Respiration as a Survival Readout for Neisseria meningitidis

(2011) Puiying A. Mak et al.   Clinical and Vaccine Immunology

The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans

(2011) Daniela Toneatto et al.   Human vaccines & immunotherapeutics

Meningococcal Disease: Shifting Epidemiology and Genetic Mechanisms That May Contribute to Serogroup C Virulence

(2011) Jessica R. MacNeil et al.   Current Infectious Disease Reports

Immunogenicity and Safety of a Multicomponent Meningococcal Serogroup B Vaccine and a Quadrivalent Meningococcal CRM197Conjugate Vaccine against Serogroups A, C, W-135, and Y in Adults Who Are at Increased Risk for Occupational Exposure to Meningococcal Isolates

(2010) Alan Kimura et al.   Clinical and Vaccine Immunology

Multicenter, Open‐Label, Randomized Phase II Controlled Trial of an Investigational Recombinant Meningococcal Serogroup B Vaccine With and Without Outer Membrane Vesicles, Administered in Infancy

(2010) Jamie Findlow et al.   CLINICAL INFECTIOUS DISEASES

Epidemiology of meningococcal disease in Latin America: current situation and opportunities for prevention

(2010) Marco Aurélio Palazzi Sáfadi et al.   NEUROLOGICAL RESEARCH

Immunogenicity of 2 Investigational Serogroup B Meningococcal Vaccines in the First Year of Life

(2010) Matthew D. Snape et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus

(2010) Marzia M. Giuliani et al.   VACCINE